VERNALIS SIGNS AGREEMENT WITH DIOSYNTH FOR MANUFACTURE OF V10153

Vernalis has signed a contract with Diosynth Biotechnology for process development, scale-up and manufacturing of V10153 for Phase III clinical trials.

V10153 is a novel thrombolytic agent that is being investigated in a Phase II study in Canada and the U.S. in patients who have recently experienced an acute ischaemic stroke.

V10153 is a modified version of human plasminogen, a naturally occurring protein, which, when activated, is responsible for dissolving blood clots in the body. The structural modification to V10153 is designed to target the drug at newly-formed blood-clots while leaving older clots unaffected, potentially reducing the risk of unwanted bleeding at other sites.